Reed Jobs shifts focus from family legacy to cancer cure ambitions in biotech venture
Executive summary: Reed Jobs told TechCrunch he prefers to talk about curing cancer rather than his last name, noting that his venture firm Yosemite now employs 17 people and is watching several blockbuster drugs lose patent protection. The shift signals growing interest and potential capital deployment in oncology ventures as patent cliffs create opportunities for biosimilars and novel therapies.
Who is involved: Reed Jobs, Yosemite venture firm, biotech industry stakeholders, and cancer patients.
Likely next: Yosemite may pursue partnerships or funding to advance oncology candidates; market participants will watch upcoming patent expiry dates for valuation impacts on large pharma.
In a recent TechCrunch interview, Reed Jobs said he would rather discuss curing cancer than his surname, highlighting his venture firm Yosemite’s growth to a 17‑person team. The firm is monitoring a group of blockbuster drugs whose patent protections are expiring, a classic patent‑cliff scenario that often opens the door to biosimilar competition and new investment. The commentary underscores a broader trend where scions of tech dynasties redirect capital toward high‑impact healthcare innovation.
Timeline
- — Reed Jobs would rather talk about curing cancer than his last name (TechCrunch)
Analysis — what this means
Sectors affected
- Oncology biotech
- Venture capital
Regulatory implications
- Patent expiry triggers FDA Abbreviated New Drug Application (ANDA) pathways for biosimilars
Historical parallels
- 2012 patent cliff for atorvastatin (Lipitor) spurred generic entry